Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Zhulin Yin
Observed name:
Z. Yin
Institution:
Institute of Cancer Research
Observed institution:
Institute of Cancer Research
ORCID:
0000-0003-4911-1708
Observed ORCID:
0000-0003-4911-1708
OpenAlex ID:
A5011880624
Implementation of platform trials in the COVID-19 pandemic: A rapid review
2021
·
Alyssa M. Vanderbeek
, Judith M. Bliss
, et al.
·
Contemporary Clinical Trials
·
68
PDF
Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov
2021
·
Julia Lai‐Kwon
, Zhulin Yin
, et al.
·
Cancer Medicine
·
36
PDF
Assessing the reporting quality of early phase dose-finding trial protocols: a methodological review
2023
·
Guillermo Villacampa
, Dhrusti Patel
, et al.
·
EClinicalMedicine
·
28
PDF
53P Assessing the reporting quality of early phase dose-finding trials
2022
·
C. Yap
, O. Solovyeva
, et al.
·
Annals of Oncology
·
19
PDF
Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects
2024
·
Zhulin Yin
, Adrian P. Mander
, et al.
·
JCO Precision Oncology
·
9
PDF
Abstract CT035: Proof-of-concept and preliminary efficacy of triple IAP blockade to maximize immunogenic cell death and induce efficient adaptive immune response: First report on the ASTEROID phase 1 trial
2024
·
Crescens Tiu
, Wing Yau
, et al.
·
Cancer Research
·
3
585P Trends in patient-reported outcome (PRO) use in early phase oncology trials
2020
·
J.E. Lai-Kwon
, Z. Yin
, et al.
·
Annals of Oncology
·
3
PDF
MC-Keyboard: A Practical Phase I Trial Design for Targeted Therapies and Immunotherapies Integrating Multiple-Grade Toxicities
2024
·
Liyun Jiang
, Zhulin Yin
, et al.
·
Journal of Immunotherapy and Precision Oncology
·
2
PDF
Show more works
View as search
Works count:
8
Citation count:
168
H-index:
5
I10-index:
4
Year
Topic
Type